Physician profile
Melissa Levack
NPI 1629273214
$41,533.27
in general payments reported to CMS, 2019-2025
24 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,857 · 2020: $2,686 · 2021: $8,249 · 2022: $7,186 · 2023: $8,447 · 2024: $3,609 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,094 · Food and Beverage: $5,359 · Travel and Lodging: $2,153 · Consulting Fee: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,093.75 |
| Food and Beverage | $5,359.18 |
| Travel and Lodging | $2,152.97 |
| Consulting Fee | $950.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22,417.78 | 2021-2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $9,495.37 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve |
| Boston Scientific Corporation | $3,886.41 | 2019-2020 | |
| Atricure, INC. | $2,283.17 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Abbott Laboratories | $624.68 | 2020-2025 | Navitor, Ensite, Epic |
| Arthrex, INC. | $482.45 | 2025 | |
| Gemini Mountain Medical, LLC | $480.97 | 2025 | |
| Baxter Healthcare | $350.31 | 2020-2025 | Preveleak |
| Getinge USA Sales, LLC | $214.58 | 2023-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Bolton Medical INC | $190.54 | 2023 | Treo Abdominal Stent-Graft System |
| Medtronic Vascular, INC. | $183.75 | 2019 | |
| Heartflow, INC. | $144.25 | 2023 | Ffrct |
| Zimmer Biomet Holdings, INC. | $130.22 | 2022 | |
| Biostable Science & Engineering | $123.10 | 2021 | |
| Abiomed | $114.42 | 2023 | Impella |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $99.76 | 2022-2024 | Angiovac |
| Stryker Corporation | $76.74 | 2024 | Na |
| Innovation Technologies INC | $49.64 | 2023-2024 | Irrisept |
| Pfizer INC. | $45.14 | 2024 | |
| Cerus Corporation | $38.72 | 2024 | Intercept Blood System For Platelets |
| Becton, Dickinson and Company | $35.74 | 2024 | Arista Ah Flexitip |
| Philips North America LLC | $24.38 | 2024 | (5091) Amb Mon & Diag Und |
| La Jolla Pharmaceutical Company | $21.72 | 2024 | Giapreza |
| Artivion, INC. | $19.43 | 2024 | On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Levack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.